Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576512 | 0.80 | CSNK2A1 (0.39) | EGFRPOLBIDO1TDO2NQO2 | |
| SCHEMBL2551647 | 0.77 | NOS3 (0.45) | ALOX5APFEN1EGFRNOS3NOS1 | |
| SCHEMBL19284550 | 0.76 | PDE10A (0.40) | EGFRIDO1TDO2PDE10A | |
| SCHEMBL30041519 | 0.75 | MAPT (0.44) | EGFRL3MBTL1MAPTPDE10A | |
| SCHEMBL23649737 | 0.75 | MAPT (0.44) | EGFRL3MBTL1MAPTPDE10A | |
| SCHEMBL29377685 | 0.74 | POLB (0.47) | ALOX5APFEN1POLBL3MBTL1MAPT | |
| SCHEMBL4790717 | 0.74 | POLB (0.47) | ALOX5APFEN1POLBL3MBTL1MAPT | |
| SCHEMBL19284662 | 0.74 | LCK (0.48) | L3MBTL1MAPTNPSR1 | |
| SCHEMBL2553699 | 0.74 | EGFR (0.36) | ALOX5APFEN1EGFRMAPTNOS3 | |
| SCHEMBL31426287 | 0.74 | NOS3 (0.45) | ALOX5APFEN1EGFRNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240336630-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2024-10-10 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| CN-117940406-A | MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4090663-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115279771-A | MAP4K1 inhibitors | 缆图药品公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220323438-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2022-10-13 | — | — | US | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-2552893-B1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | BUR DANIEL (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2552893-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121555-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | ALOX5AP 4744/4885FEN1 4511/4885EGFR 1335/4885 |
| US-20240336630-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | ALOX5AP 4776/4885FEN1 4450/4885EGFR 1321/4885 |
| US-20220323438-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | ALOX5AP 4744/4885FEN1 4511/4885EGFR 1335/4885 |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | CLIC1, IRF3, KCNH3 | ALOX5AP 3786/4885FEN1 4244/4885EGFR 2150/4885 |
| US-20230140954-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | ALOX5AP 4744/4885FEN1 4511/4885EGFR 1335/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | ALOX5AP 4744/4885FEN1 4511/4885EGFR 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.